Back to search results

Phase 2b Study of Camoteskimab for Moderate-to-Severe Atopic Dermatitis

This study is testing an investigational drug called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). Researchers want to see if camoteskimab can improve eczema symptoms compared to a placebo (an inactive substance). You may be able to join if you are 18 to 65 years old and have had chronic eczema for at least one year, with moderate-to-severe symptoms. The main goal is to measure the percentage change in your Eczema Area and Severity Index (EASI) score after 24 weeks. This study is currently recruiting 280 participants.

Study design
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study. Participants will be randomly assigned to receive one of three doses of camoteskimab or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 24, indicating follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07599813

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Recruiting
PHASE2Ages 18–65InterventionalTreatment
Apollo Therapeutics Ltd
~280 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:CamoteskimabPlacebo

At a glance

Recruiting sites
31 of 85 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage change from baseline in Eczema Area and Severity Index (EASI) between camoteskimab and placebo at Week 24
Measured over From Baseline visit until Week 24 visit

Conditions

Atopic Dermatitis
Atopic
Dermatitis
Dermatitis, Atopic
Dermatologic Disease
Eczema
Eczema Atopic Dermatitis
Eczema, Atopic

Explore related trials

Atopic Dermatitis

Where it's being run

85 sites across 28 states
Poland14
California7
Florida7
Germany7
Czechia6
Hungary6
Bulgaria5
Spain5

Who to contact

Kendra Williams
[email protected]
205-209-4101
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Completely resected basal cell or squamous cell carcinoma of the skin.
Carcinoma in situ of the cervix. 17. Has had previous exposure to anti-IL-18 therapy. 18. Known allergy/sensitivity to any component of IMP. 19. History of use of any of these medications as follows:

What this trial measures

  • Percentage change from baseline in Eczema Area and Severity Index (EASI) between camoteskimab and placebo at Week 24From Baseline visit until Week 24 visit

    An EASI score is a tool used to measure the extent (area) and severity of atopic eczema. The EASI utilizes area assessments that rate the four involved regions on a 0% to 100% scale for each region. The scores are added up for each of the four body regions (head, arms, trunk, and legs). For each of these components, the individual scores are added together to calculate the EASI score, which ranges from 0 to 72. The higher the EASI score, the more severe the AD.